Elutia (ELUT) Stock Price, News & Analysis

Company Overview

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Key Stats

• Today's Range: $3.76 to $3.99
• 50-Day Range: $2.73 to $4.35
• 52-Week Range: $1.14 to $5.24
• Volume: 10,743 shs
• Average Volume: 43,963 shs
• Market Capitalization: $93.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Elutia Stock Analysis - MarketRank™

Elutia scored higher than 72% of companies evaluated by MarketBeat, and ranked 321st out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Elutia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Elutia has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Elutia is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elutia is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.36% of the float of Elutia has been sold short.

Short Interest Ratio / Days to Cover

Elutia has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elutia has recently decreased by 30.06%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elutia does not currently pay a dividend.

Dividend Growth

Elutia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.36% of the float of Elutia has been sold short.

Short Interest Ratio / Days to Cover

Elutia has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elutia has recently decreased by 30.06%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.96

News Sentiment

Elutia has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Elutia this week, compared to 1 article on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elutia insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.80% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELUT Stock Analysis - Frequently Asked Questions

How have ELUT shares performed this year?

Elutia's stock was trading at $2.16 at the start of the year. Since then, ELUT stock has increased by 78.2% and is now trading at $3.85.
View the best growth stocks for 2024 here.

How were Elutia's earnings last quarter?

Elutia Inc. (NASDAQ:ELUT) announced its earnings results on Wednesday, August, 7th. The company reported ($1.14) earnings per share for the quarter. The company earned $6.29 million during the quarter.

Who are Elutia's major shareholders?

Elutia's top institutional investors include Nantahala Capital Management LLC (7.40%), AIGH Capital Management LLC (6.99%), Renaissance Technologies LLC (0.22%) and Arcus Capital Partners LLC (0.04%). Insiders that own company stock include Highcape Capital, LP, Birchview Capital, Lp, Matthew Ferguson, Thomas Englese, David Colpman and Brigid Makes.
View institutional ownership trends.

How do I buy shares of Elutia?

Shares of ELUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/07/2024
• Today: 9/27/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELUT
• CUSIP: N/A
• CIK: 1708527
• Web: www.elutia.com
• Phone: 240-247-1170
• Fax: 510-307-9896
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +161.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-37,660,000.00
• Net Margins: -261.08%
• Pretax Margin: -280.51%
• Return on Equity: N/A
• Return on Assets: -159.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.76
• Quick Ratio: 0.68

Sales & Book Value

• Annual Sales: $24.99 million
• Price / Sales: 3.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.66) per share
• Price / Book: -2.31

Miscellaneous

• Outstanding Shares: 24,273,000
• Free Float: 14,370,000
• Market Cap: $92.97 million
• Optionable: Not Optionable
• Beta: 0.73